Ignite Creation Date:
2025-12-25 @ 1:43 AM
Ignite Modification Date:
2025-12-26 @ 1:20 AM
Study NCT ID:
NCT05154994
Status:
RECRUITING
Last Update Posted:
2025-11-21
First Post:
2021-11-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma
Sponsor:
University of Utah
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-01-14
Start Date Type:
ACTUAL
Primary Completion Date:
2026-04-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-11-30
Completion Date Type:
ESTIMATED
First Submit Date:
2021-11-30
First Submit QC Date:
None
Study First Post Date:
2021-12-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-19
Last Update Post Date:
2025-11-21
Last Update Post Date Type:
ESTIMATED